- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | FDA's rare pediatric disease voucher program revived by 2026 government funding bill | ||
| Mi | Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026 | ||
| Mi | AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&J competition | ||
| Mi | Novartis CEO projects 2026 growth despite 'largest patent expiry' in company history | ||
| Mi | BMS celebrates US soccer legend's shutout against cancer in Breyanzi collab | ||
| Mi | OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts | ||
| Mi | As CEO, Luke Miels wants GSK to be more 'product-centric' | ||
| Mi | Amgen resists FDA request to pull rare disease drug Tavneos from the market | ||
| Di | India will invest $1.1B to boost development of biologics, biosimilars | ||
| Di | Novo shares plummet on sales, profit warning for '26 as 2 top execs head for the doors | ||
| Di | Charles River to close cell therapy CDMO site, lay off 20 staffers | ||
| Di | Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade | ||
| Di | FDA signals tailored approach to 'carefully shepherd' CAR-T therapy for autoimmune diseases | ||
| Di | BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop | ||
| Di | FDA rejects AstraZeneca's subQ Saphnelo, but company expects quick turnaround for new approval decision | ||
| Di | Sanofi sanctioned by PMCPA over CEO's 'bold claims' about Pfizer RSV vaccine | ||
| Mo | AbbVie has 'Love in Mind' with new migraine educational campaign | ||
| Mo | Thermo Fisher trims Massachusetts headcount with Franklin site closure | ||
| Mo | With FDA rejections, Aquestive's shares go up, while Pharming's go down | ||
| Mo | FDA emphasizes drug ingredients, production pledges as it debuts PreCheck manufacturing program | ||
| Mo | Regulatory tracker: FDA sets decision date for Summit's PD-1xVEGF bid | ||
| Fr | Trump administration officials are at loggerheads over future of COVID vaccines: Axios | ||
| Fr | CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns | ||
| Fr | A sales turnaround for Regeneron's Eylea franchise will have to wait at least another quarter | ||
| Fr | Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in PA |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.